Plain-English translation of NCT07548164 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Prostate Cancer research guide →Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is comparing two different ways to treat intermediate-risk prostate cancer. One group will receive irreversible electroporation (IRE), a newer treatment that uses electrical energy to destroy cancer cells in the prostate. The other group will receive the standard approach of focused radiation therapy. The goal is to find out if this new energy-based treatment works just as well as radiation.
Standard radiation therapy is effective for prostate cancer, but doctors are looking for additional options that might be equally effective while potentially offering different benefits. This trial is testing whether the new treatment could give patients another proven choice for fighting intermediate-risk prostate cancer.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will be randomly assigned to receive either the new irreversible electroporation treatment or standard radiation therapy as a boost to your regular prostate cancer treatment. The new treatment involves a procedure under general anesthesia where electrical energy is delivered to the prostate to destroy cancer cells. The standard arm involves focused radiation therapy sessions. You will have follow-up visits to monitor how well the treatment worked and watch for any side effects.
AI-generated summary from trial data · Jun 23, 2026 · Not medical advice
United States